In addition, treat-to-target, randomized controlled trials (RCTs) have demonstrated that degludec is associated with a reduced risk of hypoglycemia compared with other basal insulin analogs, at equivalent glycemic control, for patients with either T1D or T2D (11–15). Here, INS is linked to Hypoglycemia.